ReviewBiomarker research2017
Metastatic biomarkers in synovial sarcoma.
Review in Biomarker research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Biomolecular condensates as dynamic regulators of musculoskeletal homeostasis, disease, and therapeutic challenges.Bone research · 2026Review
- Diagnostic challenges in synovial sarcoma: a case report.Journal of medical case reports · 2026Article
- Proteomic and Lipidomic Atlas of Gut-Associated Lymph and Venous Depots in Female Piglets.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Core Epithelial-to-Mesenchymal Transition Gene Signature Predicts Metastasis and Poor Survival in Synovial Sarcoma.Cancer medicine · 2026Article
- Heterogeneous characteristics of γδ T cells in peripheral blood of diffuse large B-cell lymphoma.Biomarker research · 2025Article
- Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma.Science advances · 2025Article
- Challenges in diagnosing common tumors at uncommon sites.Rare tumors · 2025Article
- Genetic and Molecular Heterogeneity of Synovial Sarcoma and Associated Challenges in Therapy.Cells · 2024Review
- Novel candidate metastasis-associated genes for synovial sarcoma.Journal of cellular and molecular medicine · 2024Article
- FAM83D acts as an oncogene by regulating cell cycle progression via multiple pathways in synovial sarcoma: a potential novel downstream target oncogene of anlotinib.Discover oncology · 2024Article
- Tumor size and surgical margins are important prognostic factors of synovial sarcoma - A retrospective study.Journal of orthopaedics · 2023Article
- Primary intraventricular synovial sarcoma of the brain with recurrence - case presentation.BMC neurology · 2022Article
- Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy.Journal for immunotherapy of cancer · 2022Article
- Article
- The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives.Current treatment options in oncology · 2021Review
- Metabolic landscapes in sarcomas.Journal of hematology & oncology · 2021Review
- HDAC2 links ubiquitination to tumor suppression in synovial sarcoma.Molecular & cellular oncology · 2021Article
- Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes.Oncology letters · 2019Review
- Synovial sarcoma of the brachial plexus - a rare tumor in a rare area: a case report.Journal of medical case reports · 2018Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synovial sarcoma (SS) is an aggressive soft tissue sarcoma (STS) that typically occurs in the extremities near a joint. Metastatic disease is common and usually occurs in the lungs and lymph nodes. Surgical management is the mainstay of treatment with chemotherapy and radiation typically used as adjuvant treatment. Although chemotherapy has a positive impact on survival, the prognosis is poor if metastatic disease occurs. The biology of sarcoma invasion and metastasis remain poorly understood. Chromosomal translocation with fusion of the SYT and SSX genes has been described and is currently used as a diagnostic marker, although the full impact of the fusion is unknown. Multiple biomarkers have been found to be associated with SS and are currently under investigation regarding their pathways and mechanisms of action. Further research is needed in order to develop better diagnostic screening tools and understanding of tumor behavior. Development of targeted therapies that reduce metastatic events in SS, would dramatically improve patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.